AURUM Biosciences Ltd develops novel pharmaceuticals for use in a number of different clinical indications of high unmet medical need. Aurum is currently completing preclinical development of ABL101, its lead stroke management product, and envisages initiating clinical studies of efficacy and safety in the near future. Follow-on programmes include products for heart disease, cancer, epilepsy, and dementia. Aurum’s lead project utilises an oxygen carrier and proprietary software for use with MRI in Acute Ischaemic Stroke. Aurum has funding in place to initiate recruitment for a Phase 2 clinical study in stroke patients.
Introduction to ABL 101
Imaging life, protecting lives
This government is committed to encouraging research and innovation within our health service, so I welcome this investment in innovative stroke technology
Shona Robison, Cabinet Secretary for Health, Wellbeing, and Sport
Technology and Products, including
- Perfluorocarbon (PFC) carrying oxygen to organs and tissues
- Magnetic Resonance Imaging (MRI) a non-invasive, medical imaging technique that does not use ionising radiation
- Proprietary image analysis software for rapid and accurate analyses of images of the stroke patient’s brain
Example Patient Pathway
Aurum Biosciences has the depth and breadth of knowledge within the Board, Management Team, and Scientific Advisory Board necessary to ensure the success of the company and its exciting pipeline of products. The Aurum Management Team are experts in their respective fields. The team not only possesses a wealth of medical, scientific and technical expertise to drive the pipeline forward, but the necessary development and commercial experience required to make Aurum a success. Team members have worked previously with major pharmaceutical and successful biotechnology companies, as well as in senior academic and research positions.
In September 2015, Aurum Biosciences Ltd raised approximately $4.5m (£3m) in a combination of equity and convertible loan funds from investors in UK and USA. The investors include Tricap Ltd based in Melrose (Scotland), Scottish Investment Bank and Wellcome Trust. Management also contributed significantly to the investment. Considerable investment had previously been made to develop the company’s lead product and technology.